Fludarabine
Gastroesophageal Junction Adenocarcinoma
Explore 110 assets in Gastroesophageal Junction Adenocarcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Beijing Biotech
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07551362CT.gov Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer | — | Recruiting | — | — | — |
NCT06748872CT.gov EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma | — | Not Yet Recruiting | — | — | — |
NCT06341647CT.gov Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | — | Withdrawn | — | — | — |
NCT05678205CT.gov A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | — | Withdrawn | — | — | — |
NCT04727151CT.gov TAC T-cells for the Treatment of HER2-positive Solid Tumors | — | Terminated | — | — | — |
NCT03302403CT.gov Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Junction Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Beijing Biotech | P1/2 | CCC · 48 |
| Irinotecan | AstraZeneca | P3 | BBB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P3 | BB |
| Pembrolizumab | Eikon Therapeutics | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Levofolinic Acid | Merck Sharp & Dohme LLC | P3 | BB |
| Oxaliplatin | Alliance for Clinical Trials in Oncology | P3 | BB |
| Disitamab Vedotin | BeOne Medicines | P2 | BB |
+42 more in the Gastroesophageal Junction Adenocarcinoma cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Gastroesophageal Junction Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-gastroesophageal-junction-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →